Elgethun Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Elgethun Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.6K	Hold	15,000	–	–	﹤0.01%	174
2026 Q1	$23.7K	Hold	15,000	–	–	﹤0.01%	166
2025 Q4	$25.1K	Hold	15,000	–	–	﹤0.01%	164
2025 Q3	$25.7K	Hold	15,000	–	–	﹤0.01%	156
2025 Q2	$13.6K	Hold	15,000	–	–	﹤0.01%	150
2025 Q1	$6.77K	Hold	15,000	–	–	﹤0.01%	151
2024 Q4	$7.54K	Hold	15,000	–	–	﹤0.01%	154
2024 Q3	$13.6K	Hold	15,000	–	–	﹤0.01%	153
2024 Q2	$15K	Hold	15,000	–	–	﹤0.01%	153
2024 Q1	$21.5K	Hold	15,000	–	–	0.01%	153
2023 Q4	$16.4K	Hold	15,000	–	–	﹤0.01%	152
2023 Q3	$18K	Hold	15,000	–	–	0.01%	152
2023 Q2	$21.1K	Hold	15,000	–	–	0.01%	153
2023 Q1	$22.7K	Hold	15,000	–	–	0.01%	126
2022 Q4	$18.8K	Hold	15,000	–	–	0.01%	121
2022 Q3	$17K	Hold	15,000	–	–	0.01%	117
2022 Q2	$24K	Hold	15,000	–	–	0.01%	115
2022 Q1	$23K	Hold	15,000	–	–	0.01%	111
2021 Q4	$38K	Hold	15,000	–	–	0.01%	107
2021 Q3	$38K	Hold	15,000	–	–	0.01%	105
2021 Q2	$43K	Hold	15,000	–	–	0.01%	102
2021 Q1	$35K	Hold	15,000	–	–	0.01%	100
2020 Q4	$26K	Hold	15,000	–	–	0.01%	98
2020 Q3	$14K	Hold	15,000	–	–	0.01%	93
2020 Q2	$13K	Hold	15,000	–	–	0.01%	96
2020 Q1	$12K	Hold	15,000	–	–	0.01%	96
2019 Q4	$13K	Buy	+15,000	New	+$12.5K	0.01%	93
2019 Q3	–	Sell	-15,000	Closed	-$17K	–	96
2019 Q2	$17K	Hold	15,000	–	–	0.01%	91
2019 Q1	$20K	Hold	15,000	–	–	0.01%	90
2018 Q4	$16K	Sell	15,000 -2,145	-13%	-$3.29K	0.01%	88
2018 Q3	$35K	Hold	17,145	–	–	0.02%	82
2018 Q2	$31K	Hold	17,145	–	–	0.02%	85
2018 Q1	$40K	Hold	17,145	–	–	0.03%	93
2017 Q4	$32K	Hold	17,145	–	–	0.02%	89
2017 Q3	$43K	Hold	17,145	–	–	0.03%	85
2017 Q2	$47K	Hold	17,145	–	–	0.04%	82
2017 Q1	$52K	Hold	17,145	–	–	0.04%	76
2016 Q4	$54K	Buy	+17,145	New	+$52.6K	0.04%	128

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

RCWM

Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

TCOT

Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

BWCS

Beirne Wealth Consulting Services Shelton, Connecticut $503M AUM 27.98% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Elgethun Capital Management's LCTX Position: Q2 2026 in Review

Elgethun Capital Management held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 15,000 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #174.

Elgethun Capital Management first reported a position in LCTX in Q4 2016 and has held it in 38 quarters since. The position peaked at $54K in Q4 2016. 32 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Elgethun Capital Management held 15,000 shares of Lineage Cell Therapeutics worth $19.6K as of Q2 2026.
Elgethun Capital Management left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Elgethun Capital Management's portfolio in Q2 2026, its #174 holding.
Elgethun Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2016 and has held it in 38 quarters since.
Elgethun Capital Management's Lineage Cell Therapeutics position peaked at $54K in Q4 2016.
32 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Elgethun Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.